
    
      A Double-blind, Placebo-controlled, Randomized Study in Rheumatoid Arthritis Subjects to
      Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending
      Doses of MEDI5117 (anti-IL-6)
    
  